Is ERAS or EVMN more undervalued in 2026?

CirclFi compares Erasca, Inc. (ERAS) and Evommune, Inc. (EVMN) using 13 institutional-grade valuation models. ERAS has a Quality of Company score of 4.2/10 while EVMN scores 6.0/10.

Which is a better buy — ERAS or EVMN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ERAS and EVMN valuations compare?

ERAS at $12.20 and EVMN at $23.33 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ERAS vs EVMN Valuation Comparison 2026 — Intrinsic Value Analysis

ERAS

Biotechnology

Erasca, Inc.

Quality

4.2

out of 10

Value Trap

SAFE

Price

$12.20

Last close

Models

10/13

Active

EVMN

Biotechnology

Evommune, Inc.

Quality

6.0

out of 10

Value Trap

—

Price

$23.33

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	ERAS Fair Value	ERAS Upside	EVMN Fair Value	EVMN Upside
Bayesian DCF	Intrinsic	$3.70	-69.7%	$3.93	-83.1%
Earnings Power Value	Intrinsic	$9.40	-56.3%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.99	-91.9%	$2.55	-89.6%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ERAS vs EVMN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ERAS vs EVMN — Which Stock Is More Undervalued?

EVMN scores higher with a 6.0/10 quality rating vs ERAS's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Erasca, Inc. (ERAS) and Evommune, Inc. (EVMN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ERAS currently trades at $12.20 with a QOC of 4.2/10, while EVMN trades at $23.33 with a QOC of 6.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).